TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Dundee Corporation (TSX: DC.A) (the “Corporation” or “Dundee”) today announces that TauRx Pharmaceuticals Ltd. (“TauRx”), a leader in tau-based research in Alzheimer’s, unveiled initial data from the randomised portion of their widely followed Phase 3 clinical trial, LUCIDITY (NCT03446001). Dundee holds 1,015,008 shares in TauRx. For a copy of TauRx’s official announcement, please visit:
Read more at globenewswire.comDundee Corporation Portfolio Holding, TauRx Pharmaceuticals Ltd., Announces Move Toward Regulatory Submission Following Initial Data From LUCIDITY Trial
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
